Novo Nordisk A/S Stock News

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.

Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.

Shares of Marinus Pharmaceuticals Inc. MRNS, +4.13% gained 7.9% in premarket trading on Thursday after the company said it plans to sell its Rare Pediatric Disease Priority Review Voucher for $110 mil

My previous analysis on Novo Nordisk a few months back showed the company as overvalued and a HOLD. Following 5% drop in today's market, I still rate NVO stock as a hold. Click to know.

I wrote about Novo Nordisk a few months back, and called the company overvalued and a "Hold". It's time to update that thesis in today's market, and following a 5% drop. The company is still expensive

Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.

Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.

The Health Care sector is seen as a safety trade over recent weeks as global equities sputter. Novo Nordisk has a pipeline of drugs that should support high earnings growth in the coming years.

Henry Schein (HSIC) serves the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004.

VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) advises that the Chair of the Weste

These stocks appear to be clear winners.

Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropath

LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.

Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.

Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.